Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial

Loprinzi, Charles L.; Le‐Rademacher, Jennifer; Majithia, Neil; McMurray, Ryan P.; O’Neill, Carrie; Bendel, M.; Beutler, Andreas S.; Lachance, Daniel H.; Cheville, Andrea L.; Strick, D. M.; Black, David F.; Tilburt, Jon C.; Smith, Thomas J.

doi:10.1007/s00520-019-04881-3

Cited by 53 publications

(40 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Acupuncture was associated with low rates of grade 3 CIPN and the stabilization of CIPN symptoms. 45 Clinical studies [46][47][48][49][50][51] have reported the effect of transcutaneous electrical nerve stimulation (Scrambler therapy) on relieving symptoms related to CIPN. The results showed significant reduction in CIPN symptoms (53% reduction in pain, 44% reduction in tingling, and a 37% reduction in numbness 47 ) and a long-term effect that was maintained at each follow-up at 5 weeks, 47 10 weeks, 48 and 3 months.…”

Section: Discussionmentioning

confidence: 99%

Innovative Approach for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Pilot Study With the Hilotherm Device, the Poliambulanza Hospital Experience

et al. 2020

View full text Add to dashboard Cite

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse event of taxanes, with no effective prevention or treatment available and a highly negative impact on patient quality of life. The aim of this study is to asses that the constant application of cooled cuffs on the hands and feet prevent and mitigate CIPN. Methods: Patients with breast, gynecologic, and pancreatic cancer who received weekly paclitaxel (PTX), PTX/carboplatin, and nab-paclitaxel (nab-PTX)/gemcitabine for any indication at the therapeutic scheduled dosage were included in this prospective study. Hilotherm Chemo care device forms a closed-loop system with cuffs and tubes through which a coolant flows at a temperature of 10 °C. CIPN was monitored using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (edition 3.0), and the tolerability and side effects were scored by using the Common Terminology Criteria for Adverse Events (T4.03 2017). Results: To date, we have enrolled 64 patients. Of these, 54 (84%) completed all cooling cycles. Continuous cooling was well tolerated by all patients. No patients had grade >2 CIPN or had serious or lasting adverse events as a result of Hilotherapy. The median time to CIPN onset was 77 days for the entire population. Conclusion: Hilotherapy has good effectiveness and tolerability and seems to be able to prevent or reduce the symptoms of CIPN. We are still recruiting patients to obtain more data and to collect data at 3 months after the end of chemotherapy. Prospective studies seem to be warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Innovative Approach for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Pilot Study With the Hilotherm Device, the Poliambulanza Hospital Experience

et al. 2020

View full text Add to dashboard Cite

show abstract

“…During the eligibility assessment 520 articles were excluded. Ultimately, a total of 18 completed studies published between 2000 and 2020 were included in the present review [23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40]. The selection process is illustrated in Fig.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…In a 2-week open-label controlled study, Loprinzi et al studied the efficacy of scrambler therapy as a monotherapy versus TENS in patients with chemotherapy-induced polyneuropathy [26]. Scrambler therapy was well-tolerated and effective in reducing the pain.…”

Section: Transcutaneous Electrical and Electromagnetic Stimulationmentioning

confidence: 99%

Non-Pharmacological Management of Painful Peripheral Neuropathies: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A recent study found that the use of wireless transcutaneous electrical nerve stimulation significantly improved some measures of CIPN, including pain, numbness and tingling 139 . Furthermore, scrambler therapy (a novel transcutaneous neurostimulation technique) has been postulated as a potential treatment 140 but was no more effective than sham therapy in a recent RCT 141 .…”

Section: Non-pharmacologicalmentioning

confidence: 99%

Recent advances in understanding chemotherapy-induced peripheral neuropathy

Gordon-Williams

Farquhar-Smith

2020

F1000Res

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neuropathy (CIPN) is a common cause of pain and poor quality of life for those undergoing treatment for cancer and those surviving cancer. Many advances have been made in the pre-clinical science; despite this, these findings have not been translated into novel preventative measures and treatments for CIPN. This review aims to give an update on the pre-clinical science, preventative measures, assessment and treatment of CIPN.

show abstract

Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial

Cited by 53 publications

References 32 publications

Innovative Approach for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Pilot Study With the Hilotherm Device, the Poliambulanza Hospital Experience

Innovative Approach for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Pilot Study With the Hilotherm Device, the Poliambulanza Hospital Experience

Non-Pharmacological Management of Painful Peripheral Neuropathies: A Systematic Review

Recent advances in understanding chemotherapy-induced peripheral neuropathy

Contact Info

Product

Resources

About